Skip to content
CompoundSci
All peptides
Research vial labelled CJC-1295 with DAC, a Growth hormone secretagogue peptide studied in preclinical and clinical literature

CJC-1295 with DAC

The file here is mostly preclinical work plus clinic and community practice, not registrational trials.

The albumin binder turns a pulse into a plateau. That flattening of natural pulsatility is the main criticism in the literature.

General profile

Class
Growth hormone secretagogue
Evidence
Mixed or moderate evidence
Studied dose range
1–2 mg
Frequency in protocols
Weekly or twice weekly
Route
Subcutaneous
Half life
~6–8 days
Reconstitution
2 mL bacteriostatic water per 5 mg vial
Storage
Refrigerated, ~30 days

Timing and cycling in the literature

Usually dosed in the evening window

Once weekly, same day each week

The albumin binder gives it a half-life measured in days, so the hour is irrelevant. Holding the same weekday is what keeps levels predictable.

Reported cycle: 12 weeks on, 6 weeks off

A half-life of six to eight days means levels take weeks to build and weeks to clear, so cycles are long by necessity.

Watch for: Carpal tunnel symptoms, swelling and glucose. Effects persist long after the last injection.

What it conflicts with

Three separate questions, kept separate. A hard stop means the mechanisms must not run together at all and timing does not fix it. A syringe rule means the same day is fine but one barrel is not. Redundancy is not dangerous, it is paying twice to hit one target.

  • Hard stopTiming

    CJC-1295 with DAC + CJC-1295 without DAC

    Same compound, two release profiles

    One holds a plateau for days while the other pulses for half an hour. Running both means continuous stimulation on top of the pulse you were trying to preserve.

  • Hard stopTiming

    CJC-1295 with DAC + Tesamorelin

    Do not stack GHRH analogs

    Same axis, and the DAC version is still circulating days later. Any additional GHRH analog lands on top of a level that has not cleared.

  • Pick oneRedundant, pick one

    CJC-1295 with DAC + Tesamorelin

    Same target hit twice

    Both sit on the GHRH pathway. More water retention risk, not more useful GH signal.

  • Pick oneRedundant, pick one

    CJC-1295 with DAC + Sermorelin

    Same target hit twice

    Same GHRH lane.

  • Pick oneRedundant, pick one

    CJC-1295 with DAC + CJC-1295 without DAC

    Same target hit twice

    Same molecule with and without the albumin binder. One release profile at a time.

Most syringe compatibility claims here are practice and expert consensus, not peer reviewed mixing studies. A clear liquid after mixing does not prove the compounds are still active, and cloudiness, particles or gelling means discard. Active cancer, pregnancy, major cardiac care and heavy immunosuppression override every stack preference on this page.

See how CJC-1295 with DAC fits your week

The injection scheduler spaces doses using the clinical timing data, flags the pairs above before you draw them, and tells you why.

Model this in the injection scheduler

The studies

Human trials: No completed human efficacy trial that establishes a dose for the use people are chasing.

Open questions: Treat published dosing as observed practice, not a validated protocol.

Published papers

Indexed from Europe PMC and refreshed weekly. Each link opens the paper itself.

Search the full literature